FDA REFORM REVISIONS ON EVE OF SENATE DEBATE LEAVE MAIN PHARMACEUTICAL ISSUES UNRESOLVED; JULY 22 FLOOR TIME PLANNED BY SEN. LOTT IF TIME AGREEMENT REACHED
Executive Summary
A revised version of the Senate FDA reform bill (S 830) addresses numerous medical device-related issues but leaves most of the outstanding pharmaceutical-related provisions unresolved on the eve of floor debate.